Anti-Monkey/Human CD20 Antibody (2H7) 

Anti-Monkey/Human CD20 Antibody (2H7) is a mouse-derived IgG2b κ type antibody inhibitor, targeting to monkey/human CD20. Anti-Monkey/Human CD20 Antibody (2H7) specifically deplete B cells. Anti-Monkey/Human CD20 Antibody (2H7) can be used for the researches of inflammation and metabolic disease, such as diabetes and experimental autoimmune encephalomyelitis^[1][2].

Mouse

CD20

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Monkey/Human CD20 Antibody (2H7) (0.25-0.5 mg/kg, i.v., 9-day period with 4 injections at 3-day intervals) is effective B cells depletion and delays the progression of diabetes in hCD20-transgenic NOD mice^[1].
Anti-Monkey/Human CD20 Antibody (2H7) (200 μg, i.p., weekly) prevents or reverses myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis (EAE) in hCD20 transgenic C57BL/6 mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

931  [NCBI]

P11836-1

150 kDa

[Anti-Monkey/Human CD20 Antibody (2H7)]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hu CY, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest. 2007 Dec;117(12):3857-67.  [Content Brief]

  [2]. Weber MS, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol. 2010 Sep;68(3):369-83.  [Content Brief]